From: Cancer-related fatigue and activities of daily living: lessons learned from the COVID-19 pandemic
 | n (%) | FACIT-F score | VAS of CRF | |||
---|---|---|---|---|---|---|
Mean ± SD | CI (95%) | Range | Mean(Range) | |||
All Patients | 60 (100) | 33,50 ± 10,11 | 30,68–36,03 | 11–52 | 5,42 (0–9) | |
Sex | p = 0,58, t= -0,545 º |  | ||||
Female | 44 (73,3) | 33,07 ± 10,23 | 29,84–36,00 | 11–52 | 5,77 (0–9) | |
Male | 16 (26,7) | 34,69 ± 10,01 | 29,57–39,46 | 19–47 | 4,44 (0–8) | |
SARS CoV-2 infection | p = 0,009, t=-2,684 º |  | ||||
COVID + | 8 (13,3) | 25 ± 10,40 | 18–33,12 | 11–43 | 7,12 (3–9) | |
COVID - | 52 (86,7) | 34,81 ± 9,50 | 32,21–37,2 | 14–52 | 5,15 (0–9) | |
Type of anticancer therapy | p = 0,15, F = 1,80 ∞ |  | ||||
Chemotherapy/Endocrine | 23 | 33,87 ± 9,59 | 29,72–38,02 | 14–49 | 52 (86,7) | |
Immunotherapy | 10 | 27,10 ± 10,08 | 19,89–34,31 | 11–44 | 6,50 (3–9) | |
Radiotherapy | 4 | 34,50 ± 11,47 | 16,25–52, 6 | 19–45 | 6,00 (3–8) | |
Other or unknown | 23 | 35, 74 ± 9,92 | 31,45–40,03 | 17–52 | 4,74 (0–9) | |
Comorbidities | p = 0,54, F = 0,72 ∞ |  | ||||
Hypothyroidism | 8 (13,3) | 32,50 ± 10,78 | 23,48–41,52 | 11–45 | 6,88 (5–9) | |
Chronic pulmonary disease | 3 (5,0) | 31,33 ± 10,01 | 6,45–56,22 | 21–41 | 5,33 (3–8) | |
Depression | 2 (3,3) | 24,00 ± 5,65 | -26,82–74,82 | 20–28 | 5,50 (3–8) | |
Metastatic disease | p = 0,075, t= -1,811 ° |  | ||||
Yes | 26 | 30,85 ± 11,17 | 26,65–35,26 | 11–52 | 5,73 (0–9) | |
No | 34 | 35,53 ± 8,86 | 32,33–38,40 | 17–51 | 5,18 (0–9) |